ID: ALA4632650

Max Phase: Preclinical

Molecular Formula: C29H36O6

Molecular Weight: 480.60

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  CC1=C2[C@@H](CC1)[C@]1(C)O[C@@](C3CCCCC3)(C[C@H]1OC(=O)CO)[C@H]2OC(=O)/C=C/c1ccccc1

Standard InChI:  InChI=1S/C29H36O6/c1-19-13-15-22-26(19)27(34-24(31)16-14-20-9-5-3-6-10-20)29(21-11-7-4-8-12-21)17-23(28(22,2)35-29)33-25(32)18-30/h3,5-6,9-10,14,16,21-23,27,30H,4,7-8,11-13,15,17-18H2,1-2H3/b16-14+/t22-,23-,27+,28+,29-/m1/s1

Standard InChI Key:  SXVCCXUGYMSPTP-YDIXTDQRSA-N

Associated Targets(Human)

TRPC4/TRPC1 20 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Short transient receptor potential channel 5 300 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

A498 42825 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

UO-31 46270 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

RXF 393 41971 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 480.60Molecular Weight (Monoisotopic): 480.2512AlogP: 4.75#Rotatable Bonds: 6
Polar Surface Area: 82.06Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.13CX Basic pKa: CX LogP: 4.88CX LogD: 4.88
Aromatic Rings: 1Heavy Atoms: 35QED Weighted: 0.36Np Likeness Score: 1.88

References

1. Wu Z, Suppo JS, Tumova S, Strope J, Bravo F, Moy M, Weinstein ES, Peer CJ, Figg WD, Chain WJ, Echavarren AM, Beech DJ, Beutler JA..  (2020)  Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition.,  11  (9): [PMID:32944138] [10.1021/acsmedchemlett.0c00186]

Source